Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Geriatric Oncology Consortium
With
Tibotec Pharmaceutical Limited
Elderly NHL patients tend to tolerate the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) less well when compared to the younger population. Cardiotoxicity, as well as neutropenia, are the most common side effects in the elderly population with age being a risk factor for doxorubicin induced cardiac toxicity. Treatment related toxicity in the older population can preclude adequate therapy and potentially contribute to poor outcomes. Pegylated liposomal doxorubicin has shown similar efficacy with a significant lower incidence of cardiotoxicity ad significantly fewer cardiac events compared with conventional doxorubicin. Exploration of alternative regimens to maximize tolerability and thus enhance overall efficacy in this population is warranted. Both safety and efficacy will be evaluated.
Age
65–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 65 years and older;
Diagnosis of Non-Hodgkin's lymphoma where therapy with CHOP plus rituximab is considered;
Previously untreated;
ECOG 0-2
Adequate renal and hepatic functions;
Cardiac ejection fraction at least 50% by MUGA. No significant cardiac abnormalities by EKG;
Signed informed consent
You may not be if
CNS involvement by lymphoma;
Hypersensitivity to study drugs;
Active infection;
Prior treatment with monoclonal antibodies for cancer;
History of cardiac disease with New York Heart Association Class II or greater or clinical evidence of congestive heart failure